Memgen is a clinical-stage biotechnology company developing immunotherapies to improve the survival and quality of life of patients with cancer, autoimmune conditions and infectious diseases. Memgen's lead product, ISF35, is a first-in-class immunotherapy that targets the CD40 receptor on multiple hematologic malignancies and solid tumors including hepatocellular carcinoma, melanomas, ovarian and bladder cancers. ISF35 is currently in phase I and II clinical trials for chronic lymphocytic leukemia (CLL) and lymphomas.
Memgen's technology platform is based on the tumor necrosis factor (TNF) superfamily of molecules. Memgen's patent-protected re-engineered molecules include: ISF35, M-TNFα, M-TNFβ, M-FasL, and M-TRAIL. Memgen's viral delivery and immunotherapy approach has been validated by the recent acquisition of Biovex by Amgen for up to $1 billion for a similar viral immunotherapy product.